Drug intelligence / Profile preview

VY-X

Development stage: Preclinical
Lead developer: Vycellix
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Ex Vivo, Intravenous

Overview

VY-X is a novel small non-coding RNA construct developed by Vycellix. It is designed to enhance the efficacy of cytotoxic cellular therapies by increasing the density and load of perforin and granzyme B within cytotoxic effector cells, such as T cells and natural killer (NK) cells. This leads to higher serial killing capacity and a faster 'time-to-next-kill' for these immune cells. Potential applications include ex vivo treatment of cells prior to adoptive transfer and in vivo administration as an adjuvant with T cell and/or NK cell therapies for cancer, or as a monotherapy to boost endogenous effector cells.

Targets

GZMB (Granzyme B)PRF1 (Zinc finger protein 395)

Beyond the preview

Go deeper on VY-X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VY-X.

Explore the full profile